Table of Contents Author Guidelines Submit a Manuscript
Journal of Drug Delivery
Volume 2017 (2017), Article ID 7275985, 9 pages
https://doi.org/10.1155/2017/7275985
Review Article

Recent Advances in Hydrogel-Based Drug Delivery for Melanoma Cancer Therapy: A Mini Review

1St. Peters Institute of Pharmaceutical Sciences, Kakatiya University, Warangal, Telangana, India
2Department of Chemistry, Tulane University, New Orleans, LA, USA
3Laboratory of Nanobiomaterials, Institute of Chemistry and Natural Resources and Núcleo Científico Multidisciplinario, Universidad de Talca, Talca, Maule, Chile

Correspondence should be addressed to Esteban F. Durán-Lara

Received 10 March 2017; Revised 6 June 2017; Accepted 20 June 2017; Published 9 August 2017

Academic Editor: A. Fadda

Copyright © 2017 Sowmya Vishnubhakthula et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. T. L. Diepgen and V. Mahler, “The epidemiology of skin cancer,” British Journal of Dermatology, supplement 61, pp. 1–6, 2002. View at Google Scholar
  2. K. M. Hardy, D. A. Kirschmann, E. A. Seftor et al., “Regulation of the embryonic morphogen nodal by Notch4 facilitates manifestation of the aggressive melanoma phenotype,” Cancer Research, vol. 70, no. 24, pp. 10340–10350, 2010. View at Publisher · View at Google Scholar · View at Scopus
  3. D. S. Rigel and J. A. Carucci, “Malignant melanoma: prevention, early detection, and treatment in the 21st century,” CA: A Cancer Journal for Clinicians, vol. 50, no. 4, pp. 215–236, 2000. View at Google Scholar
  4. A. R. Hess, L.-M. Postovit, N. V. Margaryan et al., “Focal adhesion kinase promotes the aggressive melanoma phenotype,” Cancer Research, vol. 65, no. 21, pp. 9851–9860, 2005. View at Publisher · View at Google Scholar · View at Scopus
  5. R. B. Rigon, M. H. Oyafuso, A. T. Fujimura et al., “Nanotechnology-based drug delivery systems for melanoma antitumoral therapy: a review,” BioMed Research International, vol. 2015, Article ID 841817, pp. 1–22, 2015. View at Publisher · View at Google Scholar · View at Scopus
  6. J. A. Lo and D. E. Fisher, “Melanoma pathogenesis,” in RAF Targets in Melanoma: Biological Mechanisms, Resistance, and Drug Discovery, R. J. Sullivan, Ed., pp. 25–45, Springer, New York, NY, USA, 2015. View at Google Scholar
  7. U. Leiter and C. Garbe, “Epidemiology of melanoma and nonmelanoma skin cancer—the role of sunlight,” in Sunlight, Vitamin D and Skin Cancer, pp. 89–103, Springer, New York, NY, USA, 2008. View at Google Scholar
  8. F. L. Meyskens Jr., P. J. Farmer, and H. Anton-Culver, “Etiologic pathogenesis of melanoma: a unifying hypothesis for the missing attributable risk,” Clinical Cancer Research, vol. 10, pp. 2581–2583, 2004. View at Publisher · View at Google Scholar
  9. Y. Liu and M. S. Sheikh, “Melanoma: molecular pathogenesis and therapeutic management,” Molecular and Cellular Pharmacology, vol. 6, no. 3, pp. 228–251, 2014. View at Google Scholar
  10. C. Avendano and J. C. Menendez, Medicinal Chemistry of Anticancer Drugs, Elsevier, 2015.
  11. J. J. Luke and G. K. Schwartz, “Chemotherapy in the management of advanced cutaneous malignant melanoma,” Clinics in Dermatology, vol. 31, no. 3, pp. 290–297, 2013. View at Publisher · View at Google Scholar
  12. Z. Livshits, R. B. Rao, and S. W. Smith, “An approach to chemotherapy-associated toxicity,” Emergency Medicine Clinics of North America, vol. 32, no. 1, pp. 167–203, 2014. View at Publisher · View at Google Scholar · View at Scopus
  13. H. Pelicano, D. S. Martin, R.-H. Xu, and P. Huang, “Glycolysis inhibition for anticancer treatment,” Oncogene, vol. 25, no. 34, pp. 4633–4646, 2006. View at Publisher · View at Google Scholar · View at Scopus
  14. S. S. Legha, S. Ring, A. Bedikian et al., “Treatment of metastatic melanoma with combined chemotherapy containing cisplatin, vinblastine and dacarbazine (CVD) and biotherapy using interleukin-2 and interferon-,” Annals of Oncology, vol. 7, no. 8, pp. 827–835, 1996. View at Publisher · View at Google Scholar · View at Scopus
  15. S. A. Rosenberg, J. C. Yang, D. J. Schwartzentruber et al., “Prospective randomized trial of the treatment of patients with metastatic melanoma using chemotherapy with cisplatin, dacarbazine, and tamoxifen alone or in combination with interleukin-2 and interferon alfa-2b,” Journal of Clinical Oncology, vol. 17, no. 3, pp. 968–975, 1999. View at Publisher · View at Google Scholar · View at Scopus
  16. D. L. Dragu, L. G. Necula, C. Bleotu, C. C. Diaconu, and M. Chivu-Economescu, “Therapies targeting cancer stem cells: current trends and future challenges,” World Journal of Stem Cells, vol. 7, no. 9, pp. 1185–1201, 2015. View at Google Scholar
  17. R. K. Saini, R. Chouhan, L. P. Bagri, and A. Bajpai, “Strategies of targeting tumors and cancers,” Journal of Cancer Research Updates, vol. 1, pp. 129–152, 2012. View at Google Scholar
  18. V. Laquintana, A. Trapani, N. Denora, F. Wang, J. M. Gallo, and G. Trapani, “New strategies to deliver anticancer drugs to brain tumors,” Expert Opinion on Drug Delivery, vol. 6, no. 10, pp. 1017–1032, 2009. View at Publisher · View at Google Scholar · View at Scopus
  19. V. Jain, S. Jain, and S. C. Mahajan, “Nanomedicines based drug delivery systems for anti-cancer targeting and treatment,” Current Drug Delivery, vol. 12, no. 2, pp. 177–191, 2015. View at Publisher · View at Google Scholar · View at Scopus
  20. R. Singh and J. W. Lillard Jr., “Nanoparticle-based targeted drug delivery,” Experimental and Molecular Pathology, vol. 86, no. 3, pp. 215–223, 2009. View at Publisher · View at Google Scholar
  21. G. Dikmen, L. Genç, and G. Güney, “Advantage and disadvantage in drug delivery systems,” Journal of Materials Science and Engineering, vol. 5, no. 4, p. 468, 2011. View at Google Scholar
  22. K. Cho, X. Wang, S. Nie, Z. Chen, and D. M. Shin, “Therapeutic nanoparticles for drug delivery in cancer,” Clinical Cancer Research, vol. 14, no. 5, pp. 1310–1316, 2008. View at Publisher · View at Google Scholar · View at Scopus
  23. E. R. Gillies and J. M. Frechet, “Dendrimers and dendritic polymers in drug delivery,” Drug Discovery Today, vol. 10, no. 1, pp. 35–43, 2005. View at Publisher · View at Google Scholar
  24. R. Challa, A. Ahuja, J. Ali, and R. K. Khar, “Cyclodextrins in drug delivery: an updated review,” AAPS PharmSciTech, vol. 6, no. 2, pp. E329–E357, 2005. View at Publisher · View at Google Scholar · View at Scopus
  25. M. H. Schmid and H. C. Korting, “Liposomes: a drug carrier system for topical treatment in dermatology,” Critical Reviews in Therapeutic Drug Carrier Systems, vol. 11, no. 2-3, pp. 97–118, 1993. View at Google Scholar
  26. T. R. Hoare and D. S. Kohane, “Hydrogels in drug delivery: progress and challenges,” Polymer, vol. 49, no. 8, pp. 1993–2007, 2008. View at Publisher · View at Google Scholar · View at Scopus
  27. J. Li, Y. Kuang, J. Shi, Y. Gao, J. Zhou, and B. Xu, “The conjugation of nonsteroidal anti-inflammatory drugs (NSAID) to small peptides for generating multifunctional supramolecular nanofibers/hydrogels,” Beilstein Journal of Organic Chemistry, vol. 9, pp. 908–917, 2013. View at Publisher · View at Google Scholar · View at Scopus
  28. E. Caló and V. V. Khutoryanskiy, “Biomedical applications of hydrogels: a review of patents and commercial products,” European Polymer Journal, vol. 65, pp. 252–267, 2015. View at Publisher · View at Google Scholar · View at Scopus
  29. N. Chirani, L. Yahia, L. Gritsch, F. L. Motta, S. Chirani, and S. Faré, “History and applications of hydrogels,” Journal of Biomedical Sciences, vol. 4, article 2, 2015. View at Publisher · View at Google Scholar
  30. S. J. Hwang, N. Baek, H. Park, and K. Park, “Hydrogels in cancer drug delivery systems,” in Drug Delivery Systems in Cancer Therapy, D. M. Brown, Ed., pp. 97–115, Humana Press, Totowa, NJ, USA, 2004. View at Google Scholar
  31. V. H. G. Phan, E. Lee, J. H. Maeng et al., “Pancreatic cancer therapy using an injectable nanobiohybrid hydrogel,” RSC Advances, vol. 6, no. 47, pp. 41644–41655, 2016. View at Publisher · View at Google Scholar · View at Scopus
  32. R. Bharadwaj, P. J. Das, P. Pal, and B. Mazumder, “Topical delivery of paclitaxel for treatment of skin cancer,” Drug Development and Industrial Pharmacy, vol. 42, no. 9, pp. 1482–1494, 2016. View at Publisher · View at Google Scholar · View at Scopus
  33. H. W. Seo, D. Y. Kim, D. Y. Kwon et al., “Injectable intratumoral hydrogel as 5-fluorouracil drug depot,” Biomaterials, vol. 34, no. 11, pp. 2748–2757, 2013. View at Publisher · View at Google Scholar · View at Scopus
  34. Y. Sun, L. Du, Y. Liu et al., “Transdermal delivery of the in situ hydrogels of curcumin and its inclusion complexes of hydroxypropyl-β-cyclodextrin for melanoma treatment,” International Journal of Pharmaceutics, vol. 469, no. 1, pp. 31–39, 2014. View at Publisher · View at Google Scholar
  35. C. M. D. G. Marques and S. MacNeil, “Use of a tissue engineered human skin model to investigate the effects of wounding and of an anti-inflammatory on melanoma cell invasion,” PLoS ONE, vol. 11, no. 6, Article ID e0156931, 2016. View at Publisher · View at Google Scholar · View at Scopus
  36. J. Liu, C. Qi, K. Tao et al., “Sericin/dextran injectable hydrogel as an optically trackable drug delivery system for malignant melanoma treatment,” ACS Applied Materials and Interfaces, vol. 8, no. 10, pp. 6411–6422, 2016. View at Publisher · View at Google Scholar · View at Scopus
  37. L. Zhao, L. Zhu, F. Liu et al., “pH triggered injectable amphiphilic hydrogel containing doxorubicin and paclitaxel,” International Journal of Pharmaceutics, vol. 410, no. 1-2, pp. 83–91, 2011. View at Publisher · View at Google Scholar · View at Scopus
  38. M. M. Babić, B. D. Božić, B. D. Božić, J. M. Filipović, G. S. Ušćumlić, and S. L. Tomić, “Evaluation of novel antiproliferative controlled drug delivery system based on poly(2-hydroxypropyl acrylate/itaconic acid) hydrogels and nickel complex with Oxaprozin,” Materials Letters, vol. 163, pp. 214–217, 2016. View at Publisher · View at Google Scholar · View at Scopus
  39. E. Montanari, S. Capece, C. Di Meo et al., “Hyaluronic acid nanohydrogels as a useful tool for BSAO immobilization in the treatment of melanoma cancer cells,” Macromolecular Bioscience, vol. 13, no. 9, pp. 1185–1194, 2013. View at Publisher · View at Google Scholar · View at Scopus
  40. E. Agostinelli, G. Tempera, N. Viceconte et al., “Potential anticancer application of polyamine oxidation products formed by amine oxidase: a new therapeutic approach,” Amino Acids, vol. 38, no. 2, pp. 353–368, 2010. View at Publisher · View at Google Scholar · View at Scopus
  41. T. Li, M. Zhang, J. Wang et al., “Thermosensitive hydrogel co-loaded with gold nanoparticles and doxorubicin for effective chemoradiotherapy,” AAPS Journal, vol. 18, no. 1, pp. 146–155, 2016. View at Publisher · View at Google Scholar · View at Scopus
  42. S. C. Weiss, “Conventional topical delivery systems,” Dermatologic Therapy, vol. 24, no. 5, pp. 471–476, 2011. View at Publisher · View at Google Scholar
  43. D. Singh Malik, N. Mital, and G. Kaur, “Topical drug delivery systems: a patent review,” Expert Opinion on Therapeutic Patents, vol. 26, no. 2, pp. 213–228, 2016. View at Publisher · View at Google Scholar · View at Scopus
  44. Y.-H. Tsou, J. Khoneisser, P.-C. Huang, and X. Xu, “Hydrogel as a bioactive material to regulate stem cell fate,” Bioactive Materials, vol. 1, no. 1, pp. 39–55, 2016. View at Publisher · View at Google Scholar
  45. H. T. Ta, C. R. Dass, and D. E. Dunstan, “Injectable chitosan hydrogels for localised cancer therapy,” Journal of Controlled Release, vol. 126, no. 3, pp. 205–216, 2008. View at Publisher · View at Google Scholar · View at Scopus
  46. S. I. Grivennikov, F. R. Greten, and M. Karin, “Immunity, Inflammation, and Cancer,” Cell, vol. 140, no. 6, pp. 883–899, 2010. View at Publisher · View at Google Scholar · View at Scopus
  47. G. Landskron, M. de La Fuente, P. Thuwajit, C. Thuwajit, and M. A. Hermoso, “Chronic inflammation and cytokines in the tumor microenvironment,” Journal of Immunology Research, vol. 2014, Article ID 149185, 19 pages, 2014. View at Publisher · View at Google Scholar · View at Scopus
  48. M. Redpath, C. M. G. Marques, C. Dibden, A. Waddon, R. Lalla, and S. MacNeil, “Ibuprofen and hydrogel-released ibuprofen in the reduction of inflammation-induced migration in melanoma cells,” British Journal of Dermatology, vol. 161, no. 1, pp. 25–33, 2009. View at Publisher · View at Google Scholar · View at Scopus
  49. A. Monette, C. Ceccaldi, E. Assaad, S. Lerouge, and R. Lapointe, “Chitosan thermogels for local expansion and delivery of tumor-specific T lymphocytes towards enhanced cancer immunotherapies,” Biomaterials, vol. 75, pp. 237–249, 2016. View at Publisher · View at Google Scholar · View at Scopus
  50. B. Al-Lazikani, U. Banerji, and P. Workman, “Combinatorial drug therapy for cancer in the post-genomic era,” Nature Biotechnology, vol. 30, no. 7, pp. 679–692, 2012. View at Publisher · View at Google Scholar · View at Scopus
  51. F. Greco and M. J. Vicent, “Combination therapy: opportunities and challenges for polymer-drug conjugates as anticancer nanomedicines,” Advanced Drug Delivery Reviews, vol. 61, no. 13, pp. 1203–1213, 2009. View at Publisher · View at Google Scholar · View at Scopus
  52. R. Xing, K. Liu, T. Jiao et al., “An injectable self-assembling collagen-gold hybrid hydrogel for combinatorial antitumor photothermal/photodynamic therapy,” Advanced Materials, vol. 28, no. 19, pp. 3669–3676, 2016. View at Publisher · View at Google Scholar · View at Scopus
  53. S. Grijalvo, J. Mayr, R. Eritja, and D. D. Díaz, “Biodegradable liposome-encapsulated hydrogels for biomedical applications: a marriage of convenience,” Biomaterials Science, vol. 4, pp. 555–574, 2016. View at Publisher · View at Google Scholar
  54. N. T. Thanh, Magnetic Nanoparticles: from Fabrication to Clinical Applications, CRC Press, Boca Raton, Fla, USa, 2012.
  55. J. Mosafer, K. Abnous, M. Tafaghodi, H. Jafarzadeh, and M. Ramezani, “Preparation and characterization of uniform-sized PLGA nanospheres encapsulated with oleic acid-coated magnetic-Fe3O4 nanoparticles for simultaneous diagnostic and therapeutic applications,” Colloids and Surfaces A: Physicochemical and Engineering Aspects, vol. 514, pp. 146–154, 2017. View at Publisher · View at Google Scholar
  56. M. Häring, J. Schiller, J. Mayr, S. Grijalvo, R. Eritja, and D. D. Díaz, “Magnetic gel composites for hyperthermia cancer therapy,” Gels, vol. 1, no. 2, pp. 131–161, 2015. View at Publisher · View at Google Scholar